AtriCure (ATRC) Expected to Announce Earnings on Tuesday

AtriCure (NASDAQ:ATRC) is expected to be announcing its Q4 2025 results after the market closes on Tuesday, February 17th. Analysts expect AtriCure to post earnings of ($0.04) per share and revenue of $140.50 million for the quarter. Parties are encouraged to explore the company’s upcoming Q4 2025 earning overview page for the latest details on the call scheduled for Tuesday, February 17, 2026 at 4:30 PM ET.

AtriCure Stock Performance

ATRC opened at $32.65 on Friday. The stock has a 50-day moving average of $39.03 and a 200-day moving average of $36.81. The company has a debt-to-equity ratio of 0.15, a quick ratio of 2.85 and a current ratio of 3.87. AtriCure has a 52-week low of $28.29 and a 52-week high of $43.18. The company has a market cap of $1.62 billion, a PE ratio of -53.52 and a beta of 1.41.

Analysts Set New Price Targets

Several research analysts recently commented on the company. Citigroup reissued a “market outperform” rating on shares of AtriCure in a research report on Thursday, October 30th. JPMorgan Chase & Co. cut shares of AtriCure from an “overweight” rating to a “neutral” rating and set a $36.00 price target for the company. in a research note on Wednesday. Canaccord Genuity Group boosted their price objective on shares of AtriCure from $53.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Needham & Company LLC reiterated a “buy” rating and set a $45.00 price target on shares of AtriCure in a report on Thursday. Finally, Zacks Research upgraded AtriCure from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, January 6th. One investment analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $52.83.

Insiders Place Their Bets

In other AtriCure news, insider Justin J. Noznesky sold 5,166 shares of the firm’s stock in a transaction that occurred on Wednesday, November 26th. The shares were sold at an average price of $37.29, for a total value of $192,640.14. Following the sale, the insider owned 78,798 shares in the company, valued at $2,938,377.42. This trade represents a 6.15% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director Sven Wehrwein sold 5,033 shares of the company’s stock in a transaction on Monday, November 24th. The stock was sold at an average price of $37.32, for a total transaction of $187,831.56. Following the transaction, the director owned 34,374 shares of the company’s stock, valued at $1,282,837.68. This trade represents a 12.77% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders sold 18,166 shares of company stock valued at $676,378. 3.50% of the stock is currently owned by corporate insiders.

Institutional Trading of AtriCure

Hedge funds have recently made changes to their positions in the company. Geneos Wealth Management Inc. acquired a new position in shares of AtriCure in the second quarter valued at approximately $37,000. Smartleaf Asset Management LLC raised its stake in shares of AtriCure by 59.8% during the fourth quarter. Smartleaf Asset Management LLC now owns 1,146 shares of the medical device company’s stock valued at $46,000 after acquiring an additional 429 shares during the last quarter. State of Wyoming bought a new position in shares of AtriCure during the fourth quarter valued at $75,000. Strs Ohio acquired a new position in shares of AtriCure during the first quarter worth $158,000. Finally, Tower Research Capital LLC TRC grew its stake in shares of AtriCure by 502.9% in the second quarter. Tower Research Capital LLC TRC now owns 5,492 shares of the medical device company’s stock worth $180,000 after purchasing an additional 4,581 shares during the last quarter. 99.11% of the stock is owned by institutional investors and hedge funds.

About AtriCure

AtriCure, Inc is a medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation (AF) and related conditions. Founded in 2000 and headquartered in Mason, Ohio, AtriCure has established itself as a leader in surgical ablation devices designed to interrupt the errant electrical pathways that cause AF. The company’s solutions are used by cardiac surgeons and electrophysiologists to reduce the risk of stroke and improve patient outcomes in the treatment of both paroxysmal and persistent AF.

The company’s product portfolio centers on its Synergy Surgical Ablation System, which delivers controlled radiofrequency energy in a minimally invasive format, and the cryoICE Cryoablation System, which offers an alternative ablation modality using precise freezing techniques.